244 related articles for article (PubMed ID: 9688051)
21. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers.
Alsenz J; Steffen H; Alex R
Pharm Res; 1998 Mar; 15(3):423-8. PubMed ID: 9563072
[TBL] [Abstract][Full Text] [Related]
22. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.
Wu X; Whitfield LR; Stewart BH
Pharm Res; 2000 Feb; 17(2):209-15. PubMed ID: 10751037
[TBL] [Abstract][Full Text] [Related]
23. Flow cytometric functional analysis of multidrug resistance by Fluo-3: a comparison with rhodamine-123.
Koizumi S; Konishi M; Ichihara T; Wada H; Matsukawa H; Goi K; Mizutani S
Eur J Cancer; 1995 Sep; 31A(10):1682-8. PubMed ID: 7488425
[TBL] [Abstract][Full Text] [Related]
24. P-glycoprotein substrates and antagonists cluster into two distinct groups.
Scala S; Akhmed N; Rao US; Paull K; Lan LB; Dickstein B; Lee JS; Elgemeie GH; Stein WD; Bates SE
Mol Pharmacol; 1997 Jun; 51(6):1024-33. PubMed ID: 9187269
[TBL] [Abstract][Full Text] [Related]
25. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
26. Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase--further experimental evidence for a multisite model.
Garrigos M; Mir LM; Orlowski S
Eur J Biochem; 1997 Mar; 244(2):664-73. PubMed ID: 9119038
[TBL] [Abstract][Full Text] [Related]
27. Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells.
Troutman MD; Thakker DR
Pharm Res; 2003 Aug; 20(8):1192-9. PubMed ID: 12948017
[TBL] [Abstract][Full Text] [Related]
28. Modulation of multidrug resistant in cancer cells by EGCG, tannic acid and curcumin.
Li H; Krstin S; Wink M
Phytomedicine; 2018 Nov; 50():213-222. PubMed ID: 30466981
[TBL] [Abstract][Full Text] [Related]
29. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?
Tang F; Horie K; Borchardt RT
Pharm Res; 2002 Jun; 19(6):765-72. PubMed ID: 12134945
[TBL] [Abstract][Full Text] [Related]
30. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers.
Troutman MD; Thakker DR
Pharm Res; 2003 Aug; 20(8):1200-9. PubMed ID: 12948018
[TBL] [Abstract][Full Text] [Related]
31. Localization of the 1,4-dihydropyridine drug acceptor of P-glycoprotein to a cytoplasmic domain using a permanently charged derivative N-methyl dexniguldipine.
Ferry D; Boer R; Callaghan R; Ulrich WR
Int J Clin Pharmacol Ther; 2000 Mar; 38(3):130-40. PubMed ID: 10739116
[TBL] [Abstract][Full Text] [Related]
32. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
Elsby R; Surry DD; Smith VN; Gray AJ
Xenobiotica; 2008 Jul; 38(7-8):1140-64. PubMed ID: 18668443
[TBL] [Abstract][Full Text] [Related]
33. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
34. Bodipy-FL-verapamil: a fluorescent probe for the study of multidrug resistance proteins.
Rosati A; Candussio L; Crivellato E; Klugmann FB; Giraldi T; Damiani D; Michelutti A; Decorti G
Cell Oncol; 2004; 26(1-2):3-11. PubMed ID: 15371652
[TBL] [Abstract][Full Text] [Related]
35. Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessel endothelial cell monolayers.
Fontaine M; Elmquist WF; Miller DW
Life Sci; 1996; 59(18):1521-31. PubMed ID: 8890933
[TBL] [Abstract][Full Text] [Related]
36. P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes.
Farrell RJ; Menconi MJ; Keates AC; Kelly CP
Aliment Pharmacol Ther; 2002 May; 16(5):1021-31. PubMed ID: 11966513
[TBL] [Abstract][Full Text] [Related]
37. Communication between multiple drug binding sites on P-glycoprotein.
Martin C; Berridge G; Higgins CF; Mistry P; Charlton P; Callaghan R
Mol Pharmacol; 2000 Sep; 58(3):624-32. PubMed ID: 10953057
[TBL] [Abstract][Full Text] [Related]
38. Grapefruit juice activates P-glycoprotein-mediated drug transport.
Soldner A; Christians U; Susanto M; Wacher VJ; Silverman JA; Benet LZ
Pharm Res; 1999 Apr; 16(4):478-85. PubMed ID: 10227700
[TBL] [Abstract][Full Text] [Related]
39. Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine.
Riffkin CD; Chung R; Wall DM; Zalcberg JR; Cowman AF; Foley M; Tilley L
Biochem Pharmacol; 1996 Nov; 52(10):1545-52. PubMed ID: 8937469
[TBL] [Abstract][Full Text] [Related]
40. Differential Coupling of Binding, ATP Hydrolysis, and Transport of Fluorescent Probes with P-Glycoprotein in Lipid Nanodiscs.
Li MJ; Nath A; Atkins WM
Biochemistry; 2017 May; 56(19):2506-2517. PubMed ID: 28441502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
